Equities research analysts predict that FibroGen (NASDAQ:FGEN) will report $28.23 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for FibroGen’s earnings, with the highest sales estimate coming in at $29.00 million and the lowest estimate coming in at $27.40 million. FibroGen reported sales of $26.89 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 5%. The business is expected to issue its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that FibroGen will report full year sales of $192.38 million for the current year, with estimates ranging from $127.00 million to $225.00 million. For the next fiscal year, analysts forecast that the business will post sales of $358.32 million per share, with estimates ranging from $281.00 million to $464.80 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for FibroGen.
FibroGen (NASDAQ:FGEN) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.01. The business had revenue of $42.51 million for the quarter, compared to analyst estimates of $45.37 million. FibroGen had a negative net margin of 100.43% and a negative return on equity of 32.08%.
A number of equities analysts have recently issued reports on FGEN shares. Zacks Investment Research lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. ValuEngine upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. BidaskClub upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Leerink Swann restated an “outperform” rating and set a $88.00 target price (up from $80.00) on shares of FibroGen in a research report on Wednesday, February 28th. Finally, TheStreet upgraded shares of FibroGen from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. FibroGen presently has an average rating of “Hold” and an average price target of $66.67.
Shares of FGEN opened at $47.40 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.70 and a current ratio of 9.70. The company has a market cap of $3,972.15, a PE ratio of -27.40 and a beta of 1.89. FibroGen has a 12-month low of $24.60 and a 12-month high of $63.00.
In related news, insider K Peony Yu sold 10,000 shares of FibroGen stock in a transaction on Monday, January 29th. The shares were sold at an average price of $62.00, for a total value of $620,000.00. Following the transaction, the insider now directly owns 152,086 shares in the company, valued at approximately $9,429,332. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Pat Cotroneo sold 49,500 shares of FibroGen stock in a transaction on Friday, February 16th. The shares were sold at an average price of $55.96, for a total transaction of $2,770,020.00. Following the completion of the transaction, the vice president now owns 207,392 shares in the company, valued at $11,605,656.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 433,799 shares of company stock worth $23,216,568. 13.60% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the stock. Bank of Montreal Can grew its position in FibroGen by 2,097.2% in the 4th quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 3,041 shares during the last quarter. Fortaleza Asset Management Inc. boosted its position in shares of FibroGen by 95.0% during the 4th quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 1,700 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of FibroGen by 41.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 1,147 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its position in shares of FibroGen by 112.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,410 shares of the biopharmaceutical company’s stock worth $237,000 after purchasing an additional 2,336 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of FibroGen during the 4th quarter worth $255,000. Hedge funds and other institutional investors own 61.39% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “FibroGen (FGEN) Expected to Announce Quarterly Sales of $28.23 Million” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/17/fibrogen-fgen-expected-to-announce-quarterly-sales-of-28-23-million.html.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Get a free copy of the Zacks research report on FibroGen (FGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.